Sun Pharmaceutical Industries’ and certain of its subsidiaries have executed settlement agreement with ‘The Medicines Company, USA’ settling the lawsuit filed in the United States against the company and its subsidiaries regarding submission of an Abbreviated New Drug Application (ANDA) by one of subsidiaries, for a generic version of Angiomax, Bivaliruding injection. This product is a direct thrombin inhibitor indicated for use as an anticoagulant.
Under the terms of the settlement agreement, the company’s subsidiary is entitled to launch its version of generic Angiomax in the United States on June 30, 2019 or earlier under certain limited circumstances.
Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
